Table 5. Bivariate sensitivity analysis for MenACWY compared with MenC at 14 months.
| Incremental cost-effectiveness ratios [€/QALY (95% CI)] | |||||
| Average duration of protection for MenACWY after vaccination at 14 monthsa | |||||
| Price differential b | ACWY: 6 y | ACWY: 5 y | ACWY: 4 y | ACWY: 3 y | ACWY: 2 y |
| - €5,- | c.s. | c.s. | c.s. | c.s. | €907,349c |
| - €1,- | c.s. | c.s. | c.s. | c.s. | €170,984c |
| €0,- | c.s. | c.s. | c.s. | c.s. | d |
| €1,- | €15,622 | €25,162 | €46,753 | €143,724 | d |
| €2,- | €44,576 | €63,865 | €107,335 | €301,923 | d |
| €3,- | €73,529 | €102,569 | €167,918 | €460,122 | d |
| €4,- | €102,483 | €141,273 | €228,501 | €618,321 | d |
| €5,- | €131,347 | €179,976 | €289,084 | €776,520 | d |
QALY = quality adjusted life year, c.s. = cost-saving. Costve price differential indicates that MenACWY is cheaper than MenC. 14 months in a loss of QALYs if the duration of protect.
a
The average duration of protection of MenC is held constant at 4 years.
b
A negative price differential indicates that MenACWY is cheaper than MenC.
c
ICER expresses the costs saved per QALY lossed.
d
For these scenarios, MenACWY vaccination at 14 months costs more and saves less QALYs than MenC vaccination.